UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2022

Commission File Number: 001-39487

 

 

Silence Therapeutics plc

(Exact Name of Registrant as Specified in Its Charter)

 

 

72 Hammersmith Road

London W14 8TH

United Kingdom

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

Filed as Exhibit 99.1 to this Report on Form 6-K is a press release of Silence Therapeutics plc, dated August 11, 2022.

EXHIBIT LIST

 

Exhibit

   

Description

99.1    Press release, dated August 11, 2022, “Silence Therapeutics Announces Pricing of Underwritten Offering”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: August 12, 2022     SILENCE THERAPEUTICS PLC
    By:  

/s/ Craig Tooman

      Name: Craig Tooman
      Title: Chief Executive Officer
Silence Therapeutics (PK) (USOTC:SLNCF)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Silence Therapeutics (PK) Charts.
Silence Therapeutics (PK) (USOTC:SLNCF)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Silence Therapeutics (PK) Charts.